Gilead Sold $873 Million Worth of its Antiviral COVID-19 Treatment Even Though Data on its Success Remains Mixed
Read Full Article
- Gilead posted its first numbers detailing how much money the pharmaceutical company has made through Veklury, a COVID-19 antiviral treatment.
- Gilead sold $873 million worth of Veklury, also known as remdesivir, in three months.
- The FDA authorized Veklury as the first antiviral treatment approved to treat COVID-19 patients.
- Studies on the effectiveness of Veklury present mixed results...